<DOC>
	<DOCNO>NCT02521844</DOCNO>
	<brief_summary>This Phase 1A/B study consist two part . Part A non-randomised , open-label , sequential evaluation safety , pharmacokinetics , MTD , RD ETC 1922159 patient advanced metastatic , unresectable solid malignancy , approve treatment option standard care available . Dose escalation , goal identify MTD RD , guide oCRM model cohort size one patient . Part B non-randomised , non-comparative , open-label evaluation safety tolerability RD ETC 1922159 patient advanced metastatic , unresectable solid malignancy , approve treatment option standard care available , molecular phenotype expect make sensitive PORCN inhibitor treatment . It anticipate study take approximately 30 month complete ( approximately 18 month Part A approximately 12 month Part B ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability ETC-1922159 Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>18+ yr ( US ) , 21+ yr ( Singapore ) Histologically/cytologically confirm advanced/metastatic unresectable solid tumor , treatment option Radiologically confirm disease progression Evaluable/measurable disease RECIST ECOG 02 Life expectancy ≥3 mo Organ function : Absolute neutrophil count ≥1.0×109/L Platelets ≥100×109/L ( w/o transfusion w/in 21 day ) Hemoglobin ≥9 g/dL PT PTT w/in ≤1.5× ULN INR ≤1.5× ULN Total bilirubin ≤1.5× ULN AST and/or ALT ≤2.5× ULN , &lt; 5× ULN w/liver metastasis Creatinine clearance ≥60 mL/min Total Ca ( correct serum albumin ) w/in normal limit Mg ≥ low limit normal Normal urinalysis Pts w/ osteopenia ( Tscore 1 2.5 L/R total hip , L/R femoral neck lumbar spine [ L1L4 ] ) eligible Neg pregnancy test Part B : Tumor tissue available biopsy consent provide , archival tumor tissue available pt provide consent , predose biopsy do Tumor tissue receptive Wnt signal biopsy Male w/partner ( ) ( childbearing ) unwilling use contraception Female childbearing potential , unless birth control use study 12 wks posttreatment . Pregnant/nursing female Current anticancer therapy w/in 4 wks prestudy w/Grade ≤1 side effect resolve w/in 4 wks prestudy Other IPs w/in 4 wks 5 halflives ( whichever longer ) prior study drug Malignancy remission w/in last 3 yr ( exception : basal skin squamous cell carcinoma situ cervix cancer ) CNS metastasis , unless treat w/ surgery , whole brain radiation stereotactic radiosurgery , stable disease ≥8 wks w/o steroid use ≥4 wks prior study drug Radiation w/in 4 wks , limited field radiation w/in 2 wks , prior study drug , w/unresolved Grade ≤1 side effect Radiation spine/pelvis bone chemoradiation pelvic organ Surgical procedure w/in 4 wks start study drug . Or pt surgeryrelated complication Grade ≤1 Interstitial lung disease , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis Bisphosphonate therapy ( osteoporosis symptomatic hypercalcaemia ) denosumab ( osteoporosis ) prior study drug Osteoporosis ( Tscore &lt; −2.5 L/R total hip , L/R femoral neck , lumbar spine [ L1L4 ] DEXA scan ) Symptomatic vertebral fragility fracture fragility fracture hip , pelvis , wrist , location ( fragility fracture fracture w/out trauma result fall ≤standing height ) Moderate ( 25 % 40 % decrease vertebral ht . ) severe ( &gt; 40 % decrease vertebral ht . ) morphometric vertebral fracture βCTX &gt; 1000 pg/mL ( morning ≥10hrs fasting ) Thyrotropin/25hydroxyvitamin D level &lt; low limit normal Bone metastases ≥1 follow : Pathologic fracture Lytic lesion require orthopedic intervention Long QT prolong QTc ( &gt; 460 m ) Thiazolidinedione peroxisome proliferatoractivated receptor gamma agonist ( e.g . Actos® [ pioglitazone ] Avandia® [ rosiglitazone ] ) w/in 4 wks prior study drug PO IV glucocorticoid ≥4 wks daily dose eq . ≥7.5 mg PO prednisone w/in 12 wks prior study drug dose Hyperparathyroidism , Paget 's disease osteomalacia Bleeding disorder/coagulopathy Heparin , warfarin similar anticoagulant ( except . low molecular weight heparin treatment/prophylaxis ) currently w/in 4 wks study drug Heart failure , ischemic heart disease , uncontrolled hypertension , uncontrolled diabetes mellitus , psychiatric condition , ongoing cardiac arrhythmia require medication ( Grade ≥2 , NCI CTCAE v. 4.03 ) , significant/unstable concurrent medical illness investigator opinion HIV active bacterial , viral fungal infection Gastric bypass Part B : • APC , CTNNB1 , WTX [ FAM123 ] , AXIN1 GSK3B tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>responsive Wnt signalling regulation</keyword>
</DOC>